Veteran engagement in opioid tapering research: a mission to optimize pain management

Luana Colloca\textsuperscript{a,b,c,*}, Nkaku R. Kisaalita\textsuperscript{d}, Marcel Bizien\textsuperscript{e,f}, Michelle Medeiros\textsuperscript{g}, Friedhelm Sandbrink\textsuperscript{h,i}, C. Daniel Mullins\textsuperscript{g}

More than 50 million Americans suffer from chronic pain, and approximately 20 million individuals have severe chronic pain that interferes with life or work activities.\textsuperscript{15} This is a particular concern for the Veterans Health Administration (VHA) as chronic pain has been found to be more common, severe, and complex in Veterans.\textsuperscript{32,40} In addition to chronic pain, military Veterans often suffer from other complex medical and mental health issues.\textsuperscript{33}

Opioid analogesics are often used to treat chronic noncancer pain (CNCP); however, there is insufficient evidence that long-term use improves chronic pain or functioning.\textsuperscript{9,24} Furthermore, long-term opioid use is associated with increased mood disorders prevalence\textsuperscript{1} and several potential harms including overdose (OD), the development of opioid use disorder (OUD), and possibly death. Nearly 10 million Americans misuse or abuse opioids, which may elevate the risk for developing OUD. An estimated 2 million individuals have OUD, and to date, approximately 450,000 people have died by OD from prescription or illicit opioids. Approximately 81,230 drug OD deaths occurred in the United States in the 12 month ending in May 2020.\textsuperscript{36} One study showed that Veterans were twice as likely to die from accidental OD compared with non-Veterans, indicating a strong correlation to dose and to mental health comorbidities.\textsuperscript{6}

The 2017 Veterans Health Administration /Department of Defense (DoD) Clinical Practice Guideline for Opioid Therapy recommends against initiating long-term opioid therapy for chronic pain.\textsuperscript{19,39} Similarly, the Centers for Disease Control and Prevention recommends additional caution for prescribing >50 mg morphine equivalent daily dose (MEDD) and recommends against >90 mg MEDD.\textsuperscript{18} In general, the recommendation is to keep opioid therapy at the lowest dosage and shortest duration possible, in conjunction with the implementation of opioid risk mitigation strategies\textsuperscript{26} and consideration of issues related to telehealth, care coordination, stepped care model implementation,\textsuperscript{19} and suicide prevention.\textsuperscript{34}

Unfortunately, there are no generally accepted clinical guidelines for opioid tapering that are evidence based. Furthermore, there is no clear scientific evidence regarding the optimal speed of tapering or consistent/scheduled taper vs individualized tapers with frequent adjustments. Moreover, fears surrounding opioid tapering often lead to high dropout rates in these studies making this a challenging area to research.\textsuperscript{25}

The dearth of published comparative effectiveness studies of tapering in patients on long-term opioids for CNCP represents a major clinical dilemma.\textsuperscript{4} The CDC guidelines suggest 10% to 20% reduction per week as "reasonable" but also noted that for many patients a much slower taper would be appropriate.\textsuperscript{16,30} In 2019, the Department of Health and Human Services issued an opioid tapering guide, warning against opioids tapered rapidly or discontinued suddenly, and stated that slower tapers (eg, \(\leq 10\%\) per month) are often better tolerated than more rapid tapers.\textsuperscript{2,38}

The VHA/DoD Clinical Practice Guidelines mentions a reduction by 5% to 20% per month as most common, with the formal recommendation to evaluate patients for tapering individually.\textsuperscript{39} A systematic review by Frank et al. stated that there is overall only "very low-quality evidence" regarding interventions that may be effective to reduce or discontinue long-term opioid therapy.\textsuperscript{18} However, pain, function, and quality of life could improve with opioid dosage reduction, with best evidence derived from a small number of studies using behavioral therapies in support of opioid tapering.\textsuperscript{18} Murphy et al.\textsuperscript{31} demonstrated that patients with CNCP could be successfully tapered off of opioids within an interdisciplinary treatment program by use of a concealed taper with blinded dosage of hydromorphone. A recent RCT from Sullivan et al. also showed that an outpatient opioid tapering support intervention resulted in improvements in pain interferences, self-efficacy, and perceived opioid-related problems.
compared with usual care. Few studies have explored the patient’s perspectives on opioid tapering emphasizing a need to bolster patient-centered engagement strategies for these critical stakeholders. There are different and biased beliefs about barriers influencing opioid tapering outcomes that exist among both patients and healthcare providers, making it difficult to implement novel strategies to reduce opioids for pain management. Importantly, providers and patients’ expectancies greatly impact pain outcomes when opioids are used. The power of treatment expectancy in improving pain-related outcomes is most clearly demonstrated in experiments comparing open vs hidden administration of morphine in patients who underwent thoracotomy to remove lung cancer. The patients’ knowledge about a therapy seems to be fundamental to induce optimal therapeutic effects. These observations have been extended and corroborated by brain imaging studies showing that the mere awareness of receiving a treatment potentiates the pharmacological analgesic effect in both healthy subjects and patients with neuropathic pain.

The literature demonstrates that an individual’s expectation of a drug’s effect critically influences its therapeutic efficacy, with regulatory brain mechanisms differing as a function of expectancy. Therefore, in a novel methodological twist, we anticipate that patients who are not aware of the exact time of tapering will experience better outcomes for pain perception, interference, and mood-related outcomes. Based on this overall dearth of literature, and on the recent literature providing evidence that pain, function, and quality of life may improve with opioid reduction and that sham opioids may help reduce pain, we believe that Veterans suffering from CNCP can benefit from concealed tapering. However, ethical concerns may arise whenever use of tapering is concealed as misleading patients. The option of being debriefed about the timing of the taper. The taper schedule does involve nondisclosure of the fact that the administration meets ethical standards and is not misleading. Certain patients may not be appropriate for this tapering approach. This may include those on low MEDs who are not appropriate for rescue (i.e., “breakthrough”) medications and patients with comorbid complex opioid dependence who may be more appropriate for other OUD treatments (e.g., buprenorphine).

Such a tapering approach could benefit from the 10-step patient engagement framework. In accordance with the Patient-Centered Outcome Research Institute principles and the 10-step patient engagement framework, a vehicle to implement novel opioid tapering informed by consensus recommendations to improve the lives of CNCP Veterans. The engagement should follow these principles.

1. Reciprocal relationships and shared decision-making

Patients and stakeholders (“stakeholder partners”) would need to be involved in discussions that resulted in decisions about the study design and plans for study implementation and dissemination. During the study, and as dissemination activities occur, stakeholders should have a vote in the decision-making processes. A stakeholder advisory board of patients and partners should be created to encourage discussion about what is important to patients throughout the life of the study and to promote a culture within study governance that values all perspectives; vetting all members’ ideas in the same manner as ideas from our researchers. Patient-centered shared decision-making will bolster Veterans’ confidence in the study aims and promote greater trust in VHA services.

2. Colearning

Stakeholder partners would guide—and, in some cases, lead—the interpretation and/or dissemination of findings and the development of engagement strategies. As data emerge, stakeholder partners would be actively involved in its assessment. For example, patients may serve as representatives on the study’s data safety monitoring board. Conference calls would allow dialogue and real-time discussions among stakeholder partners and researchers to promote bidirectional learning. Researchers should be given opportunities to hear from stakeholder partners to enhance researchers’ understanding of the significance and potential impact of evidence and lessons learned. Importantly, all parties will be educated about principles of human subjects’ protection, historical lessons learned from failures to prioritize patient stakeholders, and existing opioids tapering guidelines and empirical evidence. Patient stakeholders will be involved in the dissemination of the results, including article feedback and conference presentations.

3. Partnership

The team’s researchers should form a strong partnership with their stakeholders. Input from all parties will help to establish a reasonable time commitment and set of activities for stakeholder partners. All parties should partner with designing the study, implementing, and disseminating what is learned in a manner that will be easy to understand for patients and caregivers and stakeholders.

In summary, novel-tapering approaches have the potential to improve pain and functioning for CNCP Veterans on opioid analogesics. However, the success of this line of scientific inquiry is completely dependent on the partnership of all VHA stakeholders—patients, caregivers, clinicians, and researchers. The feasibility, acceptability, and efficacy of concealed tapering studies are contingent on VHA stakeholder shared decision-making, colearning, and collaboration at every stage of the
research strategic plan—from pilot testing to large scale controlled trials. The authors hope that this perspective piece will provide guidance for investigators committed to advancing the science of opioid risk mitigation and pain management.

Disclosures

This work was funded by the Agency for Healthcare Research and Quality (R24HS022135, C.D.M./L.C.), MPowering the State: Strategic Partnership Grant (L.C.), and University of Maryland Center for Addiction Research, Education, and Service (CARES, L.C.). Dr. Colloca reports grants from Alcohol Abuse and Alcoholism (R13-AA28424), grants from National Center for Complementary and Integrative Health (R01AT01033), personal fees from Chiesi, personal fees from Averitas, and personal fees from USATXW, during the conduct of the study. C.D. Mullins reports personal fees from AstraZeneca, Bayer Pharmaceuticals, Merck, Pfizer, Sanofi, and Takeda, outside the submitted work. The remaining authors have no conflicts of interest to declare.

Article history:
Received 26 February 2021
Received in revised form 10 April 2021
Accepted 17 April 2021

References

[1] AstraZenlun L, Zerbo K, Bishop TM, Britton PC. Opioid use disorders, psychiatric comorbidities, and risk for suicide attempts among veterans seeking pain management. J Gen Intern Med 2020;35:2107–16. doi: 10.1007/s11606-020-05649-4
[2] Available at: https://www.hhs.gov/about/news/2019/10/10/hhs-announces-guide-appropriate-tapering-or-discontinuation-long-term-opioid-use.html. 2019.
[3] Bedford T, Adediran T, Haycock NR, Mullins CD, Medeiros M, Wright T, Curato L, Hamlin L, Colloca L. Patient and provider acceptability of a patient preauthorized concealed opioid reduction. Pain Med 2021; pnaa454 In press: 1–9. doi: 10.1093/pm/pnaa454
[4] Bena C, Kulich RJ, Rathmell JP. Tapering long-term opioid therapy in chronic noncancer pain: evidence and recommendations for everyday practice. Mayo Clin Proc 2015;90:828–42.
[5] Bingel U, Wanigaasekera V, Wiech K, Ni Mhuircheartaigh R, Lee MC, Ploner M, Tracey I. The effect of treatment expectation on drug efficacy: imaging the analytic benefit of the opioid remifentanil. Sci Transl Med 2011;3:70ra14.
[6] Bohnt AS, Igen MA, Galesa S, McCarthy JF, Blow FC. Accidental poisoning mortality among patients in the department of veterans affairs health system. Med Care 2011;49:393–6.
[7] Bok S. The ethics of giving placebos. Sci Am 1968;228:13–21.
[8] Brody H, Colloca L, Miller FG. The placebo phenomenon: implications for medical education and training. JAMA Intern Med 2012;172:730–2.
[9] Brody H, Colloca L, Miller FG. The placebo effect and its relevance for clinical practice. Psychosom Med 2011;73:598–603.
[10] Colloca L, Lapiano L, Lanotte M, Benedetti F. Overt versus covert treatment for pain, anxiety, and Parkinson’s disease. Lancet Neurol 2004;3:679–87.
[11] Colloca L, DeGrazia D. Placebo effects are not just an illusion. Lancet Neurol 2005;4:418–20.
[12] Colloca L, Enck P, DeGrazia D. Placebo responding: a scoping review. PAIN 2016;157:1500–8.
[13] Colloca L. Tell me the truth and I will not be harmed: informed consents and nocebo effects. Am J Bioeth 2017;17:46–8.
[14] Covington EC, Argoff CE, Ballantyne JC, Cowan P, Gazelka HM, Hooten WM, Sites SG, Manhnapa A, Murphy A, Stanos J, Stamos SP, Jr, Sullivan MD. Ensuring patient protections when TaperingOpioids: consensus panel recommendations. Mayo Clin Proc 2020;95:2155–71.
[15] Dahlhamer J, Lucas J, Zelaya C, Nahin R, Mackey S, DeBar L, Kerns R, Von Korff M, Porter L, Helmick C. Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults - United States, 2016. MMWR. Morbidity and mortality weekly report 2018;67:1001–6.
[16] Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA 2016;315:1624–45.
[17] Franke JW, Levy C, Matlock DD, Calcatera SL, Mueller SR, Koester S, Binswanger IA. Patients’ perspectives on tapering of chronic opioid therapy: a qualitative study. Pain Med 2016;17:1838–47.
[18] Frank JW, Lovejoy TI, Becker WC, Morasbo CJ, Koening CJ, Hofflecker L, Dischinger HR, Dobscha SK, Krebs EE. Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: a systematic review. JAMA Intern Med 2017;167:181–91.
[19] Frank JW, Bohnt ASB, Sandbrink F, McGuire M, Drexl K. Implementation and policy recommendations from the VHA state-of-the-art conference on strategies to improve opioid safety. J Gen Intern Med 2020;35(supp 3):983–7.
[20] Frieden TR, Houry D. Reducing the risks of relief—the CDC opioid-prescribing guideline. N Engl J Med 2016;374:1501–4.
[21] Kissilaitis N, Staud R, Hurley R, Robinson M. Placebo use in pain management: the role of medical context, treatment efficacy, and deception in determining placebo acceptability. PAIN 2014;155: 2638–45.
[22] Kissilaitis NR, Hurley RW, Staud R, Robinson ME. Placebo use in pain management: a mechanism-based educational intervention enhances placebo treatment acceptability. J Pain 2016;17:957–69.
[23] Klinger R, Kothe R, Schmitz J, Kamping S, Flor H. Placebo effects of a sham opioid solution: a randomized controlled study in patients with chronic low back pain. PAIN 2017;158:1893–902.
[24] Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, Kroenke K, Bar BJ, Noroobidouchi S. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA 2018;319:872–82.
[25] Kruta GP, Hjøsted J, Spgren P. Tapering off long-term opioid therapy in chronic non-cancer pain patients: a randomized clinical trial. Eur J Pain 2015;19:1228–43.
[26] Kuiper K, Anderson J, Boume D, Chen E, Peterson K. Benefits and harms of long-term opioid dose reduction or discontinuation in patients with chronic pain: a rapid review. J Gen Intern Med 2020;35(supp 3):93–44.
[27] Manhnapa A, Sullivan MD, Ballantyne JC, MacLean RR, Becker WC. Complex persistent opioid dependence with long-term opioids: a gray area that needs definition, better understanding, treatment guidance, and policy changes. J Gen Intern Med 2020;35(supp 3):964–71.
[28] Matthews MS. Opioid tapering and the patient-provider relationship. J Gen Intern Med 2020;35:8–9.
[29] Miller FG, Colloca L. The placebo phenomenon and medical ethics: rethinking the relationship between informed consent and risk-benefit assessment. Theor Med Bioeth 2011;32:209–24.
[30] Mullins CD, Abdulhalbam AM, Lavallee DC. Continuous patient engagement in comparative effectiveness research. JAMA 2012;307: 1587–8.
[31] Murphy JL, Clark ME, Banou E. Opioid cessation and multidimensional outcomes after interdisciplinary chronic pain treatment. Clin J Pain 2013; 29:100–17.
[32] Nahin RL. Severe pain in veterans: the effect of age and sex, and comparisons with the general population. J Pain 2017;18:247–54.
[33] O’Malley KA, Vinson L, Pless Kaiser A, Sager Z, Hinrichs K. Mental health and aging veterans: how the veterans health administration meets the needs of aging veterans. Public Pol Aging Rep 2020;30:19–23.
[34] Oliver EM, Bowe T, Manhnapa A, Kertesz S, Hah JM, Henderson P, Robinson A, Paik M, Sandbrink F, Gordon AJ, Trafford JA. Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. BMJ 2020;368:m283.
[35] Petersen GL, Finnernub NP, Norskov KN, Grosen K, Pilegaard HK, Benedetti F, Bie JM. Placebo manipulations reduce hyperalgesia in neuropathic pain. PAIN 2012;153:1292–300.
[36] Prevention CDC. HAN archive - 00438. Health Alert Network (HAN), 2020. Available at: cdc.gov.
[37] Revery SM. Listening to narratives from the Tuskegee syphilis study. Lancet 2011;377:1646–7.
[38] Rich, R, Chou T, Mariano ER, Legred Dopp A, Sullenger B, Burstin H, and the Pain Management Guidelines and Evidence Standards Working Group of the Action Collaborative on Countering the U.S. Opioid Epidemic. Best Practices, Research Gaps, and Future Priorities Working to Support Tapering Patients on Long-Term Opioid Therapy for Chronic
Non-Cancer Pain in Outpatient Settings. NAM Perspectives. Discussion Paper, National Academy of Medicine, Washington, DC, 2020. doi: 10.31478/202008c.

[39] Rosenberg JM, Bilka BM, Wilson SM, Spevak C. Opioid therapy for chronic pain: overview of the 2017 US department of veterans affairs and US department of defense clinical practice guideline. Pain Med 2018;19: 928–41.

[40] Sandbrink F, Oliva EM, McMullen TL, Aylor AR, Harvey MA, Christopher ML, Cunningham F, Minegishi T, Emmendorfer T, Perry JM. Opioid prescribing and opioid risk mitigation strategies in the veterans health administration. J Gen Intern Med 2020;35(suppl 3):927–34.

[41] Schanberg LE, Mullins CD. If patients are the true north, patient-centeredness should guide research. Nat Rev Rheumatol 2019;15:5–6.

[42] Sheridan S, Schrandt S, Forsythe L, Hilliard TS, Paez KA. Advisory panel on patient E. The PCORI engagement rubric: promising practices for partnering in research. Ann Fam Med 2017;15:165–70.

[43] Sullivan MD, Turner JA, Dilodovico C, D’Appolonia A, Stephens K, Chan YF. Prescription opioid taper support for outpatients with chronic pain: a randomized controlled trial. J Pain 2017;18:308–18.

[44] Wen LS, Lloyd MC. Prescribing opioids for chronic pain. JAMA 2016;316:774.

[45] Wendler D, Miller FG. Deception in the pursuit of science. Arch Intern Med 2004;164:597–600.

[46] Zhong B, Huang Y, Liu Q. Mental health toll from the coronavirus: social media usage reveals Wuhan residents’ depression and secondary trauma in the COVID-19 outbreak. Comput Hum Behav 2021;114:106624.